EP Patent

EP4385574A3 — Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Assigned to University of California · Expires 2024-10-02 · 2y expired

What this patent protects

A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.

USPTO Abstract

A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4385574A3
Jurisdiction
EP
Classification
—
Expires
2024-10-02
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.